Stem-cell islet cells and type 1: what the zimislecel results really show
A 2025 trial found most people given Vertex’s stem-cell islet therapy no longer needed insulin after a year. What that early result does, and doesn’t, mean.
A trial reported in June 2025 gave people with type 1 an infusion of insulin-making cells grown in a lab, and 10 of the 12 who received a full dose no longer needed insulin a year later. Those cells are called islet cells, the clusters in the pancreas that make insulin and that type 1 destroys. This is a real result in real people, not a mouse study, which is why it made headlines. The catch is big and honest: to stop the immune system attacking the new cells, everyone in the trial has to take anti-rejection drugs for life.
- The therapy, called zimislecel, uses islet cells grown from stem cells (master cells that can be turned into many cell types), so it does not depend on scarce donor organs.
- 10 of 12 people on a full dose were insulin-independent at one year, meaning they no longer needed insulin from a pen or pump.
- Everyone needs lifelong immunosuppression (anti-rejection medicines that quiet the immune system), which carries its own risks, such as a higher chance of infection.
- This was a small, early trial published in a major medical journal, so it is a landmark step, not a finished cure.
- It changes nothing about your insulin today, and reaching UK patients would take larger trials, then approval, then NHS funding, which is years off.
What the trial actually showed
The results were presented at a large diabetes research conference in June 2025 and published in the New England Journal of Medicine, one of the most respected medical journals. In the trial, people with type 1 received an infusion of islet cells made from stem cells. The idea is simple to state: replace the insulin-making cells the immune system destroyed, so the body can make its own insulin again.
Of the 12 people given a full dose, 10 were insulin-independent at one year, meaning they came off insulin entirely. That is a striking figure, and it is worth being clear about what kind of evidence it is: a small, early-phase trial with a year of follow-up. Small and early does not mean unimportant. It means the next questions, does it last, and is it safe over many years, are still open.
Why lifelong anti-rejection drugs are the trade
The reason this is not yet a cure for everyone comes down to the immune system. Type 1 happens because the immune system attacks insulin-making cells, and it will attack new ones too. To stop that, everyone in the trial takes immunosuppression: anti-rejection medicines that dampen the immune response for as long as the cells need to survive. Those drugs work, but they raise the risk of infection and bring side effects of their own, so they are a serious trade, not a free win.
This is why the islet transplants that already exist, using donor cells, are offered only to a small group who have the hardest time with type 1, such as people with severe hypos they cannot feel coming. A version grown from stem cells could one day remove the donor shortage, but the immune problem stays. For someone managing type 1 now, the message is steady: genuine progress to follow, and nothing that changes your own insulin today.